Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Zacks.com on MSN11d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekThe FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
GlobalData on MSN11d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
12don MSN
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback